Review
Gastroenterology & Hepatology
Luis Tellez, Agustin Albillos
Summary: Non-selective beta-blockers (NSBBs) are essential for the treatment and prevention of variceal bleeding in cirrhotic patients. However, they should be used with caution in patients with ascites, as they may impair cardiac and renal function.
LIVER INTERNATIONAL
(2022)
Article
Medicine, Research & Experimental
Susana Almenara, Beatriz Lozano-Ruiz, Ivan Herrera, Paula Gimenez, Cayetano Miralles, Pablo Bellot, Maria Rodriguez, Jose M. Palazon, Fabian Tarin, Hector Sarmiento, Ruben Frances, Jose Manuel Gonzalez-Navajas, Sonia Pascual, Pedro Zapater
Summary: This study analyzes the impact of chronic NSBB treatment on immune activation and disease progression in stable outpatients with cirrhosis. The results show that NSBB treatment is associated with significantly lower levels of IL-6 and reduced risk of adverse events.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Rafael Paternostro, Jeannette Becker, Benedikt Silvester Hofer, Vera Panagl, Helena Schiffke, Benedikt Simbrunner, Georg Semmler, Philipp Schwabl, Bernhard Scheiner, Theresa Bucsics, David Bauer, Teresa Binter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger
Summary: This study found that HVPG response is of great value in predicting the effectiveness of NSBB treatment in patients with NASH cirrhosis and varices. It can reduce the occurrence of decompensation and death, as well as the risk of variceal bleeding.
DIGESTIVE AND LIVER DISEASE
(2022)
Letter
Gastroenterology & Hepatology
Mathias Jachs, Rafael Paternostro, Thomas Reiberger, Mattias Mandorfer
Summary: This article is linked to the papers by Paternostro et al, providing links to view these papers.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Ana Garcia Garcia de Paredes, Candid Villanueva, Carolina Blanco, Joan Genesca, Nicolo Manicardi, Juan Carlos Garcia-Pagan, Jose Luis Calleja, Carlos Aracil, Rosa M. Morillas, Maria Poca, Beatriz Penas, Salvador Augustin, Juan G. Abraldes, Eldimar Alvarado, Felix Royo, Maria Laura Garcia-Bermejo, Juan Manuel Falcon-Perez, Rafael Banares, Jaime Bosch, Jordi Gracia-Sancho, Agustin Albillos
Summary: The study found that miR-181b-5p is a promising biomarker for identifying patients with compensated cirrhosis at risk of developing ascites.
Article
Gastroenterology & Hepatology
Candid Villanueva, Agustin Albillos, Joan Genesca, Joan C. Garcia-Pagan, Anna Brujats, Jose L. Calleja, Carles Aracil, Rafael Banares, Rosa M. Morillas, Maria Poca, Beatriz Penas, Salvador Augustin, Juan G. Abraldes, Edilmar Alvarado, Ferran Torres, Jaume Bosch
Summary: This study found that bacterial infections have a significant impact on the natural history of compensated cirrhosis, significantly increasing the risk of decompensation and death.
JOURNAL OF HEPATOLOGY
(2021)
Review
Medicine, General & Internal
Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Robert Schierwagen
Summary: Despite vasoconstrictor activation, patients with liver cirrhosis experience hyperdynamic circulatory disturbance. Non-selective beta-blockers have been established as a therapy to lower portal pressure and protect against variceal hemorrhage. The beneficial effect of the alpha and beta receptor blocking medication, carvedilol, and its consequences in liver cirrhosis patients have not been sufficiently investigated.
FRONTIERS IN MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Luke D. Tyson, Stephen Atkinson, Robert W. Hunter, Michael Allison, Andrew Austin, James W. Dear, Ewan Forrest, Tong Liu, Emma Lord, Steven Masson, Joao Nunes, Paul Richardson, Stephen D. Ryder, Mark Wright, Mark Thursz, Nikhil Vergis
Summary: This study aimed to determine the incidence of acute kidney injury (AKI), its association with mortality, and serum biomarkers for predicting AKI in alcohol-related hepatitis. The results showed that AKI was associated with 90-day mortality independently of liver function, and prednisolone therapy reduced the incidence of AKI. IL-8 and several miRNAs were identified as potential biomarkers for predicting AKI.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Yang An, Xiangbo Xu, Tianshu Ren, Zhenhua Tong, Fernando Gomes Ronneiro, Andrea Mancuso, Xiaozhong Guo, Xingshun Qi
Summary: The study investigated the adherence to non-selective beta blockers (NSBBs) in cirrhotic patients to prevent variceal bleeding and found a significant proportion of patients had poor adherence during hospitalizations. Factors contributing to poor adherence included refusal or forgetfulness to take medication and monitor heart rate. Older age was significantly associated with poor adherence, and patients with poor adherence were more likely to develop variceal bleeding after discharge, indicating a need for further research on improving patient adherence to NSBBs.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Karen Vagner Danielsen, Jens Dahlgaard Hove, Puria Nabilou, Meng Yin, Jun Chen, Mirabella Zhao, Thomas Kallemose, Ane Sogaard Teisner, Hartwig Roman Siebner, Richard L. Ehman, Soren Moller, Flemming Bendtsen
Summary: MR elastography can reflect portal hypertension in patients with liver cirrhosis, but the effect of NSBB treatment is significant on spleen stiffness, while inconsistent on liver stiffness. Changes in stiffness cannot predict the effect of NSBB on HVPG.
LIVER INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Huan Liu, Shirin Geravandi, Ausilia Maria Grasso, Saheri Sikdar, Alberto Pugliese, Kathrin Maedler
Summary: This study found no association between enteroviral infection in the pancreas and T2D diabetes. Despite similarities in inflammatory markers in islets in both T1D and T2D, long-term enteroviral infiltration is a distinct pathological feature of T1D-associated autoimmunity and T1D pancreases.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Pharmacology & Pharmacy
Sheng-Fu Liu, Chih-Kuo Lee, Kuan-Chih Huang, Lian-Yu Lin, Mu-Yang Hsieh, Ting-Tse Lin
Summary: The study found that the use of beta-blockers in rheumatoid arthritis (RA) patients can reduce the all-cause mortality after myocardial infarction (MI). Among them, treatment with non-selective beta-blockers was significantly associated with a lower risk of mortality.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Agustin Albillos, Aleksander Krag
Summary: Non-selective beta-blockers (NSBBs) have been the standard treatment for bleeding from oesophageal varices, but the best clinical use of NSBBs remains uncertain. This article aims to define the therapeutic window of NSBBs in cirrhosis from an individualized perspective. The use of NSBBs in patients without varices lacks robust evidence, while carvedilol appears superior to propranolol. The clinical risk-to-benefit ratio worsens in advanced decompensated stages, with high risk in patients with refractory ascites, low blood pressure, and renal impairment.
JOURNAL OF HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
David Vidal Gonzalez, Karla Paola Perez Lopez, Sail Andre Vera Nungaray, Luis Guillermo Moreno Madrigal
Summary: Ascites is the accumulation of fluid in the peritoneal cavity, often seen in patients with liver cirrhosis. The management of ascites varies depending on the severity of hemodynamic disturbance and other symptoms. Recent evidence suggests the benefits of non-selective beta-blockers for the survival rate of patients with end-stage cirrhosis and ascites.
GASTROENTEROLOGIA Y HEPATOLOGIA
(2022)
Article
Multidisciplinary Sciences
Srinivasa P. S. Rao, Matthew K. Gould, Jonas Noeske, Manuel Saldivia, Rajiv S. Jumani, Pearly S. Ng, Olivier Rene, Yen-Liang Chen, Marcel Kaiser, Ryan Ritchie, Amanda Fortes Francisco, Nila Johnson, Debjani Patra, Harry Cheung, Colin Deniston, Andreas D. Schenk, Wilian A. Cortopassi, Remo S. Schmidt, Natalie Wiedemar, Bryanna Thomas, Rima Palkar, Nahdiyah A. Ghafar, Vanessa Manoharan, Catherine Luu, Jonathan E. Gable, Kah Fei Wan, Elmarie Myburgh, Jeremy C. Mottram, Whitney Barnes, John Walker, Charles Wartchow, Natasha Aziz, Colin Osborne, Juergen Wagner, Christopher Sarko, John M. Kelly, Ujjini H. Manjunatha, Pascal Maeser, Jan Jiricek, Suresh B. Lakshminarayana, Michael P. Barrett, Thierry T. Diagana
Summary: Millions of people in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections. Researchers have identified a class of cyanotriazoles (CTs) that have potent trypanocidal activity and can potentially be used for the treatment of Chagas disease and human African trypanosomiasis. These CT compounds act by selectively and irreversibly inhibiting trypanosomal topoisomerase II and stabilizing DNA:enzyme cleavage complexes.